Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACh inhibitor (Attillaps Holdings, cutaneous autoimmune diseases)
- Development stage
- Preclinical
- Lead developer
- Attillaps Holdings
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Attillaps Holdings is developing a topical small molecule acetylcholine (ACh) inhibitor for the treatment of unspecified cutaneous autoimmune diseases. This asset is part of a broader platform focused on modulating the cutaneous cholinergic system to address inflammatory and autoimmune skin conditions. By utilizing a topical route of administration, the therapy is designed to concentrate its anti-inflammatory effects within the skin layers while minimizing systemic absorption and potential off-target effects. The program is currently in the preclinical stage of development and aims to reduce cutaneous autoimmune-driven inflammation.
- Other names
- ACh modulatoracetylcholine inhibitor
02
Targets
AcetylcholinesterasemAChR (Muscarinic acetylcholine receptors)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on ACh inhibitor (Attillaps Holdings, cutaneous autoimmune diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACh inhibitor (Attillaps Holdings, cutaneous autoimmune diseases).